Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis
Journal of Gynecologic Oncology · 2025 · 36 (1)
DOI: 10.3802/jgo.2025.36.e6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Youwen Zhu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Research Project of Xiangya Hospital, Changsha Natural Science Foundation of Hunan Provincial of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: Pembrolizumab and dostarlimab are immune checkpoint inhibitors that target programmed death receptor 1 (PD-1). Combination anti-PD-1 regimens have been shown to exhibit favorable survival benefits when treating advanced endometrial cancer (EC). Which treatment was preferable will need to be confirmed by a cost-effectiveness comparison between them. METHODS: Based on patient and clinical parameters from RUBY and NRG-GY018 phase III randomized controlled trials, the Markov model with a 20-year time horizon was established to evaluate the cost-effectiveness of dostarlimab plus chemotherapy (DC), pembrolizumab plus chemotherapy (PC), and chemotherapy alone (C) treatment for patients with mismatch repair-proficient microsatellite-stable (pMMR-MSS) and mismatch repair-deficient microsatellite instability-high (dMMR-MSI-H) advanced EC from the American payers' perspective. The main results include total cost, life-years (LYs), quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) at a $150,000/QALY of willingness-to-pay. RESULTS: In the pMMR-MSS population, DC, PC, and C produced costs (QALYs) of $99,205 (3.02), $322,530 (3.25), and $421,923 (4.40), resulting in corresponding ICERs of $974,177/QALY (PC vs. C), $234,527/QALY (DC vs. C), $86,671/QALY (DC vs. PC), respectively; In the dMMR-MSI-H population, DC, PC, and C obtained costs (QALYs) of $120,177 (5.73), $691,399 (8.43), and $708,787 (11.26), yielding ICERs of $266,423/QALY (PC vs. C), $135,165/QALY (DC vs. C), $7,866/QALY (DC vs. PC), respectively. CONCLUSION: In the US, DC was a more cost-effective treatment than PC for patients with advanced EC irrespective of MMR status. However, compared to C, DC was associated with more cost-effectiveness in the dMMR-MSI-H population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. zhuhong719@csu.edu.cn.
ORCID-Profile: Youwen Zhu, Kun Liu, Hong Zhu
Förderung
- Clinical Research Project of Xiangya Hospital
- Changsha Natural Science Foundation of Hunan Provincial of China
Zitieren
APA
Zhu, Y., Liu, K., & Zhu, H. (2025). Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis. Journal of Gynecologic Oncology, 36(1). https://doi.org/10.3802/jgo.2025.36.e6
Vancouver
Zhu Y, Liu K, Zhu H. Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis. Journal of Gynecologic Oncology. 2025;36(1). doi:10.3802/jgo.2025.36.e6
BibTeX
@article{Zhu2025,
author = {Zhu, Youwen and Liu, Kun and Zhu, Hong},
title = {Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis},
journal = {Journal of Gynecologic Oncology},
year = {2025},
volume = {36},
number = {1},
doi = {10.3802/jgo.2025.36.e6}
}
EUVIMED